Awareness of Krasnodar Territory doctors about modern approaches to the treatment of dyslipidemia and arterial hypertension
https://doi.org/10.21886/2712-8156-2021-2-1-63-69
Abstract
Aim: to assess the awareness of doctors about the main provisions of the European and Russian clinical guidelines for the management of patients with dyslipidemia and arterial hypertension (AH).
Material and methods. Anonymous survey of 584 physicians and cardiologists of Krasnodar and Krasnodar Territory was carried out. The questionnaire contained 9 multiple-choice questions.
Results: according to the results of the questionnaire, 1/3 of doctors knew the target values of low-density lipoprotein cholesterol (LDL-C) in very high-risk patients. If the target level of LDL cholesterol was not achieved on an adequate dose of statin, 75.1% of colleagues would not have added ezetimibe. For hypertriglyceridemia in patients receiving an adequate dose of statins, 47% of physicians would prescribe treatment that does not comply with clinical guidelines. More than half of the doctors gave correct answers to the questions about antihypertensive therapy. However, the target level of blood pressure was incorrectly indicated by 47.3% of respondents, 71.6% of colleagues made a mistake with the tactics of starting therapy, and 51.5% of doctors incorrectly assessed the situation with the prescription of a triple fixed combination of drugs.
Conclusion: а significant part of practicing doctors (therapists and cardiologists) were not sufficiently informed about the main provisions of the new recommendations and were guided by old (outdated) ideas.
About the Authors
V. V. Skibitskiy
Kuban State Medical University
Russian Federation
Russian Federation
Alexander V. Skibitskiy, assistant professor of Hospital Therapy.
Krasnodar
A. V. Fendrikova
Kuban State Medical University
Russian Federation
Russian Federation
Alexandra V. Fendrikova, assistant professor of Hospital Therapy.
Krasnodar
E. A. Kudrashov
Kuban State Medical University
Russian Federation
Russian Federation
Evgeniy A. Kudrashov, assistant professor of Hospital Therapy.
Krasnodar
A. V. Skibitskiy
Kuban State Medical University
Russian Federation
Russian Federation
Vitaliy V. Skibitskiy, Doctor of Medical Sciences, Professor, Head of the Department of Hospital Therapy.
Krasnodar
References
1. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В., Шальнова С.А., Яровая Е.Б., Конради А.О., Бойцов С.А. Распространенность факторов риска развития сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;10:4-12. DOI: 10.18565/cardio.2014.10.4-12
2. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart J. 2018;39,3021-3104. doi: 10.1093/eurheartj/ehy339.
3. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
4. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-40. DOI: 10.34687/2219-8202.JAD.2020.01.0002
5. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;3(25): 149-218. DOI: 10.15829/1560-4071-2020-3-3786
6. Pandor A., Ara R.M., Tumur I., Wilkinson A.J., Paisley S., Duenas A., Durrington P.N., Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265(5):568-580. doi: 10.1111/j.1365-2796.2008.02062.x.
7. Leiter L.A., Bays H., Conard S., Bird S., Rubino J., Hanson M.E. et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008;102(11):1495-501. doi: 10.1016/j.amjcard.2008.09.076
8. Смирнова Е.А., Тереховская Ю.В., Молодцова А.А., Якушин С.С. Артериальная гипертония в Рязанской области: данные третьего среза исследования ЭПОХА. Российский кардиологический журнал. 2019;24(6):49-53. doi: 10.15829/1560-4071-2019-6-49-53
9. Скибицкий В.В., Фендрикова А.В., Спиропулос Н.А., Олейник Н.И., Сиротенко Д.В. Какие причины ограничивают назначение статинов в реальной клинической практике? (по результатам опроса врачей г. Краснодара и Краснодарского края). Кардиоваскулярная терапия и профилактика. 2008;7(3):89-94. eLIBRARY ID: 9952282
Review
For citations:
Skibitskiy V.V., Fendrikova A.V., Kudrashov E.A., Skibitskiy A.V. Awareness of Krasnodar Territory doctors about modern approaches to the treatment of dyslipidemia and arterial hypertension. South Russian Journal of Therapeutic Practice. 2021;2(1):63-69. (In Russ.) https://doi.org/10.21886/2712-8156-2021-2-1-63-69
Views:
723
Email this article 